Lexicon Pharmaceuticals Inc
LXRX1.230USD
0.000
Close 12/26, 16:00（ET）Quotes delayed by 15 min
446.98MMarket Cap
LossP/E TTM
More Details of Lexicon Pharmaceuticals Inc Company
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the research and development of pilavapadin, LX9851 and sotagliflozin and the commercialization of INPEFA. It is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. It has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. It is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. It is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.
Lexicon Pharmaceuticals Inc Info
Ticker SymbolLXRX
Company nameLexicon Pharmaceuticals Inc
IPO dateApr 07, 2000
CEOExton (Michael)
Number of employees103
Security typeOrdinary Share
Fiscal year-endApr 07
Address2445 Technology Forest Blvd
CityTHE WOODLANDS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code77381
Phone12818633000
Websitehttps://www.lexpharma.com/
Ticker SymbolLXRX
IPO dateApr 07, 2000
CEOExton (Michael)
Company Executives of Lexicon Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Raymond (Ray) Debbane
Mr. Raymond (Ray) Debbane
Independent Chairman of the Board
Independent Chairman of the Board
1.39M
+2.73%
Dr. Alan J. Main, Ph.D.
Dr. Alan J. Main, Ph.D.
Executive Vice President - Innovation and Chemical Sciences
Executive Vice President - Innovation and Chemical Sciences
339.10K
--
Mr. Philippe J. Amouyal
Mr. Philippe J. Amouyal
Independent Director
Independent Director
285.17K
+14.82%
Mr. Brian T. Crum
Mr. Brian T. Crum
Senior Vice President, General Counsel
Senior Vice President, General Counsel
260.81K
--
Mr. Christopher J. (Chris) Sobecki
Mr. Christopher J. (Chris) Sobecki
Independent Director
Independent Director
203.87K
+22.03%
Dr. Samuel L. (Sam) Barker, Ph.D.
Dr. Samuel L. (Sam) Barker, Ph.D.
Independent Director
Independent Director
124.46K
+42.00%
Dr. Judith L. Swain, M.D.
Dr. Judith L. Swain, M.D.
Independent Director
Independent Director
85.17K
+76.11%
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Independent Director
Independent Director
36.81K
--
Ms. Wendy E. Mcdermott
Ms. Wendy E. Mcdermott
Senior Vice President of Human Resources
Senior Vice President of Human Resources
--
--
Ms. Kristen L. Alexander
Ms. Kristen L. Alexander
Vice President - Finance and Accounting
Vice President - Finance and Accounting
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Raymond (Ray) Debbane
Mr. Raymond (Ray) Debbane
Independent Chairman of the Board
Independent Chairman of the Board
1.39M
+2.73%
Dr. Alan J. Main, Ph.D.
Dr. Alan J. Main, Ph.D.
Executive Vice President - Innovation and Chemical Sciences
Executive Vice President - Innovation and Chemical Sciences
339.10K
--
Mr. Philippe J. Amouyal
Mr. Philippe J. Amouyal
Independent Director
Independent Director
285.17K
+14.82%
Mr. Brian T. Crum
Mr. Brian T. Crum
Senior Vice President, General Counsel
Senior Vice President, General Counsel
260.81K
--
Mr. Christopher J. (Chris) Sobecki
Mr. Christopher J. (Chris) Sobecki
Independent Director
Independent Director
203.87K
+22.03%
Dr. Samuel L. (Sam) Barker, Ph.D.
Dr. Samuel L. (Sam) Barker, Ph.D.
Independent Director
Independent Director
124.46K
+42.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 25
Updated: Tue, Nov 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Artal International S.C.A.
37.47%
Invus Public Equities Advisors, LLC
10.71%
Fidelity Management & Research Company LLC
10.64%
The Vanguard Group, Inc.
2.62%
Ulys, L.L.C.
1.50%
Other
37.05%
Shareholders
Shareholders
Proportion
Artal International S.C.A.
37.47%
Invus Public Equities Advisors, LLC
10.71%
Fidelity Management & Research Company LLC
10.64%
The Vanguard Group, Inc.
2.62%
Ulys, L.L.C.
1.50%
Other
37.05%
Shareholder Types
Shareholders
Proportion
Investment Advisor
65.77%
Hedge Fund
3.56%
Investment Advisor/Hedge Fund
2.08%
Individual Investor
1.18%
Research Firm
0.33%
Venture Capital
0.09%
Bank and Trust
0.02%
Family Office
0.01%
Other
26.96%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
304
260.48M
71.73%
-53.78M
2025Q2
320
279.54M
76.92%
-43.06M
2025Q1
325
276.43M
76.32%
-62.57M
2024Q4
309
308.33M
85.37%
-6.09M
2024Q3
300
300.67M
83.18%
-4.62M
2024Q2
291
290.96M
80.51%
+37.02M
2024Q1
279
184.47M
74.41%
-20.75M
2023Q4
274
194.11M
79.36%
-11.88M
2023Q3
271
200.84M
82.07%
-4.66M
2023Q2
276
200.76M
82.17%
+43.01M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Artal International S.C.A.
136.18M
37.47%
--
--
Jun 30, 2025
Invus Public Equities Advisors, LLC
38.92M
10.71%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
38.14M
10.49%
+3.59M
+10.41%
Jun 30, 2025
The Vanguard Group, Inc.
8.85M
2.44%
-706.14K
-7.39%
Jun 30, 2025
Ulys, L.L.C.
5.45M
1.5%
--
--
Dec 05, 2024
Millennium Management LLC
1.64M
0.45%
+1.64M
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.17M
0.87%
-6.04M
-65.57%
Jun 30, 2025
Sessa Capital
3.00M
0.83%
+3.00M
--
Jun 30, 2025
CIBC Private Wealth Management
2.45M
0.67%
+210.40K
+9.39%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.67%
Texas Capital Texas Small Cap Equity Index ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.05%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
Schwab U.S. Small-Cap ETF
0.01%
Fidelity MSCI Health Care Index ETF
0%
Global X Russell 2000 ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
FlexShares Morningstar US Market Factor Tilt Index Fund
0%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.67%
Texas Capital Texas Small Cap Equity Index ETF
Proportion0.07%
ProShares Ultra Nasdaq Biotechnology
Proportion0.06%
Invesco Nasdaq Biotechnology ETF
Proportion0.05%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.03%
Schwab U.S. Small-Cap ETF
Proportion0.01%
Fidelity MSCI Health Care Index ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
SPDR Portfolio MSCI Global Stock Market ETF
Proportion0%
FlexShares Morningstar US Market Factor Tilt Index Fund
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Lexicon Pharmaceuticals Inc?
The top five shareholders of Lexicon Pharmaceuticals Inc are:
Artal International S.C.A. holds 136.18M shares, accounting for 37.47% of the total shares.
Invus Public Equities Advisors, LLC holds 38.92M shares, accounting for 10.71% of the total shares.
Fidelity Management & Research Company LLC holds 38.14M shares, accounting for 10.49% of the total shares.
The Vanguard Group, Inc. holds 8.85M shares, accounting for 2.44% of the total shares.
Ulys, L.L.C. holds 5.45M shares, accounting for 1.50% of the total shares.
Artal International S.C.A. holds 136.18M shares, accounting for 37.47% of the total shares.
Invus Public Equities Advisors, LLC holds 38.92M shares, accounting for 10.71% of the total shares.
Fidelity Management & Research Company LLC holds 38.14M shares, accounting for 10.49% of the total shares.
The Vanguard Group, Inc. holds 8.85M shares, accounting for 2.44% of the total shares.
Ulys, L.L.C. holds 5.45M shares, accounting for 1.50% of the total shares.
What are the top three shareholder types of Lexicon Pharmaceuticals Inc?
The top three shareholder types of Lexicon Pharmaceuticals Inc are:
Artal International S.C.A.
Invus Public Equities Advisors, LLC
Fidelity Management & Research Company LLC
Artal International S.C.A.
Invus Public Equities Advisors, LLC
Fidelity Management & Research Company LLC
How many institutions hold shares of Lexicon Pharmaceuticals Inc (LXRX)?
As of 2025Q3, 304 institutions hold shares of Lexicon Pharmaceuticals Inc, with a combined market value of approximately 260.48M, accounting for 71.73% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -5.19%.
What is the biggest source of revenue for Lexicon Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Lexicon Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
